The therapeutic landscape of hemophilia continues to evolve at a rapid pace, providing clinicians and patients new opportunities to select treatment to address individual needs and characteristics. In this fast-moving, 1-hour accredited activity, Craig Kessler, MD, and Guy Young, MD, share their thoughts and experience with clotting factor concentrates, recombinant factor, factor VIII mimetics, rebalancing agents, and gene therapies. The safety and efficacy of late-phase investigational products are also discussed as these agents have the potential to address unmet needs and further transform patient care.
Course Credit:
1.00 AMA PRA Category 1 CreditTM
Dates:
Opens: 2024-09-27
Closes: 2025-09-27
Target Audience:
Hematologists, hematologist-oncologists, hematology nurse practitioners, hematology physician associates, and pharmacists involved in the management of patients diagnosed with hemophilia.
This activity is supported by an independent educational grant from Novo Nordisk.
-
Craig M. Kessler, MD
SOM Clinician Scholar Track – Professor
Professor of Oncology
Professor of Medicine and Pathology
Director, Division of Coagulation, Department of Laboratory Medicine
Director, Therapeutic and Cellular Apheresis Unit
Director, Comprehensive Hemophilia and Thrombophilia Treatment Center
Georgetown University Medical Center
Washington, DC -
Guy Young, MD
Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California
